ELICIT-PLANT
11.3.2024 10:01:30 CET | Business Wire | Press release
Elicit Plant, a pioneering and rapidly expanding agri-biotech company, announces the appointment of the renowned scientist and a leader in the ag-tech industry, Slavica Djonovic, Ph.D. as Chief Scientific Officer (CSO). An author of more than 20 patent family applications in the space of biomolecular and biological innovations for plant stress, her appointment reflects Elicit Plant's commitment to accelerating the transition towards sustainable and environmentally friendly agriculture. Slavica Djonovic's mission is to propel the company to a new level of innovation by developing cutting-edge solutions to help farmers worldwide combat water stress and scarcity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240308898928/en/
Slavica Djonovic, Chief Scientific Officer (Photo: Elicit Plant)
A remarkable scientific and leadership career
With over two decades of ag-tech experience, Slavica Djonovic is a respected scientific leader in the field of research and development of biological products for agriculture, especially in broad acre crops.
Slavica holds a Master of Science from Colorado State University, a Ph.D. from Texas A&M University, and she has completed her postdoctoral training at Massachusetts General Hospital and Harvard Medical School.
Her entrepreneurial spirit led her to be one of the founding scientists of Indigo Ag, a Boston-based agricultural biotechnology company. There, she played a key role as Director of Product Science, making significant contributions to product discovery, development, intellectual property, regulatory, and the launch of the company's first five microbial products. At Joyn Bio, a synthetic biology Agtech company in Boston (US), she served as Senior Director by establishing the disease control program and initiating the regulatory science approach, thus solidifying her reputation as a leader in agrotechnological innovation.
An expertise aligned with Elicit Plant's high ambitions
With a track record of over 20 patent applications in innovations related to plant stress, the vast majority of which have been internationally granted, Slavica Djonovic brings to Elicit Plant cutting-edge technical expertise and a unique strategic vision, precisely at a time when Elicit Plant is preparing to enter a new critical period of growth and innovation.
"Faced with the challenges posed by climate change, it is imperative that our agricultural sector quickly embraces innovative solutions to ensure a healthy and sustainable future for all. I am honored to join Elicit Plant, a booming pioneer in the agricultural sector, empowering farmers to effectively tackle climate upheavals. Elicit Plant's proprietary technology, EliTerra®, the consistent performance of its products internationally, and its team driven by a clear mission, are impressive," states Slavica Djonovic, CSO of Elicit Plant.
"In her new role as Chief Scientific Officer, Slavica will be tasked with amplifying Elicit Plant's scientific influence and accelerating the development of our EliTerra® Technological platform. Slavica brings with her a wealth of knowledge and unparalleled experience that will be essential levers for our evolution. We are convinced that under her scientific leadership, Elicit Plant will reach a new milestone in developing innovative solutions for agriculture," concludes Jean-François Déchant, CEO of Elicit Plant.
For more information: https://www.elicit-plant.com/press-resources/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240308898928/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom